Publication date: Available online 21 December 2017
Source:Cell Stem Cell
Author(s): Delfim Duarte, Edwin D. Hawkins, Olufolake Akinduro, Heather Ang, Katia De Filippo, Isabella Y. Kong, Myriam Haltalli, Nicola Ruivo, Lenny Straszkowski, Stephin J. Vervoort, Catriona McLean, Tom S. Weber, Reema Khorshed, Chiara Pirillo, Andrew Wei, Saravana K. Ramasamy, Anjali P. Kusumbe, Ken Duffy, Ralf H. Adams, Louise E. Purton, Leo M. Carlin, Cristina Lo Celso
Bone marrow vascular niches sustain hematopoietic stem cells (HSCs) and are drastically remodeled in leukemia to support pathological functions. Acute myeloid leukemia (AML) cells produce angiogenic factors, which likely contribute to this remodeling, but anti-angiogenic therapies do not improve AML patient outcomes. Using intravital microscopy, we found that AML progression leads to differential remodeling of vasculature in central and endosteal bone marrow regions. Endosteal AML cells produce pro-inflammatory and anti-angiogenic cytokines and gradually degrade endosteal endothelium, stromal cells, and osteoblastic cells, whereas central marrow remains vascularized and splenic vascular niches expand. Remodeled endosteal regions have reduced capacity to support non-leukemic HSCs, correlating with loss of normal hematopoiesis. Preserving endosteal endothelium with the small molecule deferoxamine or a genetic approach rescues HSCs loss, promotes chemotherapeutic efficacy, and enhances survival. These findings suggest that preventing degradation of the endosteal vasculature may improve current paradigms for treating AML.
Graphical abstract
Teaser
Multi-modal microscopy of acute myeloid leukemia progression within the bone marrow reveals focal and progressive remodeling of endosteal blood vessels coupled to loss of osteoblasts, hematopoietic stem cells (HSCs), and HSC niches. Preserving endosteal vessels increases the number of surviving HSCs and improves the efficacy of chemotherapy.http://ift.tt/2BM9fwb
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου